Phaseline

Companies › Mersana Therapeutics

Mersana Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
upifitamab rilsodotin (XMT-1536)
anti-NaPi2b antibody-drug conjugate
SLC34A2Phase 1Platinum Resistant Ovarian Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03319628upifitamab rilsodotin (XMT-1536)Phase 1Platinum Resistant Ovarian CancerOncologyMay 2023

Targets

SLC34A2 (1)

Companies with the same targets

Gilead Sciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.